Ovidrel (choriogonadotropin alfa) / EMD Serono - LARVOL DELTA

CLEAR: Corpus Luteum Function and Cardiovascular Adaptation in a Natural MOCK Cycle. (clinicaltrials.gov) - P=N/A | N=118 | Not yet recruiting | Sponsor: Universitair Ziekenhuis Brussel

New trial • Cardiovascular

COGNI-REHAB: hCG Treatment for Rehabilitation From a TBI (clinicaltrials.gov) - P1 | N=50 | Not yet recruiting | Sponsor: VA Office of Research and Development

New P1 trial • CNS Disorders • Vascular Neurology

Prevalence of an endogenous LH rise following final GnRH antagonist dose in the IVF antagonist protocol. (PubMed, Eur J Obstet Gynecol Reprod Biol ) - "All patients underwent standard IVF/ICSI treatment using the fixed GnRH antagonist protocol, with hCG (Ovitrelle® 250 µg/6500 IU) administered to trigger ovulation...As samples were collected only once daily, a true LH surge cannot be confirmed. Further research powered to look at specific GnRH antagonist regimens are needed to validate these findings and assess whether an endogenous LH rise influences important outcomes such as pregnancy and live birth rates."

Journal

Reverse-Phase High-Performance Liquid Chromatography/Mass Spectrometry (RP-LC-MS/MS, Label-Free Method) for Component Analysis of Gonadotropin Drugs. (PubMed, J Mass Spectrom) - "Many ovulation-inducing agents are used in this process, including human menopausal gonadotropin (HMG), recombinant follicle-stimulating hormone (r-FSH), recombinant luteinizing hormone (r-hLH), urinary human chorionic gonadotropin (u-hCG), and recombinant human chorionic gonadotropin (r-hCG)...This study used reverse-phase liquid chromatography with mass spectrometry (RP-LC-MS/MS) and a label-free quantitative proteomics method to analyze imported r-hFSH, r-hLH, r-hCG (Gonal-F, Luveris, and Ovidrel), three domestic HMG products (Le Baode, Man Fuxin, and Xin Yunle), and u-hCG (Li Zhu)...These results reveal significant differences in the composition of imported and domestic gonadotropin products, underscoring the need to further evaluate their biological activity and clinical effectiveness. This study provides important insights into drug selection for ART, with practical value for improving the quality of HMG drugs and making better use of them in clinical settings."

Journal

FSD-IEQ-2021-03: The impact of the intensity of ovarian stimulation on embryo quality in predicted suboptimal responders. A randomized controlled trial. (clinicaltrialsregister.eu) - P4 | N=110 | Recruiting | Sponsor: Santiago Dexeus Font Fundacio Privada | Not yet recruiting ➔ Recruiting

Enrollment open • Infertility • Sexual Disorders

A Comparative Study of the Effect of Novel Dual Trigger and Delayed HCG With Dual Trigger in Poor Responder Poseidon Group 4 Patients in Antagonist IVF Cycles. (PubMed, Adv Biomed Res) - "An antagonist regimen was used, which included approximately 300 units of gonadotropins, consisting of 150 units of Human menopausal gonadotropin (hMG) and 150 units of Synal-F. After administering a dose of Strotide injection followed by Decapeptyl and Ovitrelle injections, 12 hours later, a single HCG 5000-unit injection was administered, and 36 hours later, the puncture procedure was performed...This study showed that using Novel Dual Trigger and Delayed HCG, compared to Dual Trigger, did not significantly differ in the number of oocytes, embryos, or secondary pregnancy outcomes. These findings suggest that the Novel Dual Trigger and Delayed HCG methods could be equally effective in improving IVF outcomes for poor responder patients, providing a potential alternative for ovarian stimulation in these cases and instilling optimism for the future of IVF treatments."

Clinical • Journal • Infertility • Sexual Disorders

Can the Dual Trigger Protocol Impact Embryo Ploidy? (ISGE 2026) - "The study groups were: Choriomon (n=18), Gonapeptyl (n=452), Lupron (n=67), Ovidrel (n=87), and Gonapeptyl + Choriomon (n=478). There was a positive impact on success rates using a single trigger protocol such as Gonapeptyl, which demonstrated better outcomes compared to the dual trigger protocol. Ovarian stimulation using a dual trigger may influence embryo aneuploidy outcomes, however, future studies should be conducted to better understand the impact of the dual trigger protocol on embryonic chromosomal alterations."

Clinical

2,000 IU hCG is the optimal dose in a dual hCG/GnRH agonist trigger to achieve comparable pregnancy rates to hCG alone in fresh embryo transfers. (PubMed, J Assist Reprod Genet) - "2,000 IU hCG appears to be the optimal dose in a dual hCG/GnRH agonist trigger, resulting in similar pregnancy outcomes to an hCG trigger and low rates of OHSS among good-responder patients. Ongoing pregnancy rates were significantly lower with hCG doses under 2,000 IU in the dual trigger protocol."

Journal

Impact of Systematic Follicular Flushing on Egg Retrieval and Embryo Quality in IVF-ICSI Cycles: A Controlled Study? (PubMed, J Clin Med) - "A slight increase in slow cleavages was observed (27% vs. 23%, p = 0.04), as well as a lower oocyte maturation rate when ovulation was triggered by Ovitrelle alone...However, the controlled but non-randomised nature of this study requires cautious interpretation of the findings. Larger randomised trials, integrating dynamic assessment technologies, such as time-lapse imaging or oocyte transcriptomic analysis, are needed to refine the clinical indications of this technique and explore its underlying biological mechanisms."

Journal • Gynecology

Embryo division timings and top-quality embryo rates in GnRH-Antagonist ICSI cycles: a comparison of hCG and dual trigger methods. (PubMed, J Assist Reprod Genet) - "Dual triggering in GnRH-antagonist ICSI cycles did not improve most morphokinetic parameters, top-quality embryo rates, or clinical outcomes over hCG alone, suggesting limited benefit in general populations."

Journal

LUTI: Impact of the Presence of the Corpus Luteum on Pregnancies Obtained Through Frozen Embryo Transfer(FET) (clinicaltrials.gov) - P4 | N=334 | Recruiting | Sponsor: Fundacion Clinic per a la Recerca Biomédica | Active, not recruiting ➔ Recruiting

Enrollment open • Infertility • ENG

LUTI: Impact of the Presence of the Corpus Luteum on Pregnancies Obtained Through Frozen Embryo Transfer(FET) (clinicaltrials.gov) - P4 | N=334 | Active, not recruiting | Sponsor: Fundacion Clinic per a la Recerca Biomédica

New P4 trial • Infertility • ENG

A Comparing Study Between SJ04 and Ovidrel® in Healthy Subjects (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Suzhou Centergene Pharmaceuticals Co.,Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Gynecology • Infertility • Sexual Disorders

A Comparing Study Between SJ04 and Ovidrel® in Healthy Subjects (clinicaltrials.gov) - P1 | N=48 | Not yet recruiting | Sponsor: Suzhou Centergene Pharmaceuticals Co.,Ltd.

New P1 trial • Gynecology • Infertility • Sexual Disorders

Analytical Investigation of the Profile of Human Chorionic Gonadotropin in Highly Purified Human Menopausal Gonadotrophin Preparations. (PubMed, Int J Mol Sci) - "Highly purified human menopausal gonadotropin (HP-hMG [Menopur®, Ferring Pharmaceuticals, Saint-Prex, Switzerland]) contains a 1:1 ratio of follicle-stimulating hormone (FSH) and luteinizing hormone (LH)...Brevactid® (urinary hCG; Ferring Pharmaceuticals, Saint-Prex, Switzerland) and Ovidrel® (recombinant hCG; Merck KGaA, Darmstadt, Germany) were used as control samples...The analysis revealed 20-30% of protein impurities and a significant presence of oxidized forms in the HP-hMG samples. These findings are critical for understanding the quality, safety, and clinical profile of HP-hMG."

Journal

DOUBLE TRIGGER IN COS: EMBRYO QUALITY AND SUCCESS RATE (ASPIRE 2024) - "The pregnancy rate obtained in this study was 31.8% vs. 29.5%. Conclusions There are no significant differences were found in embryo quality and pregnancy success rate in patients who received double trigger therapy (Ovidrel and Buserelin) compared to single therapy (Ovidrel)."

Gynecology • Infertility • Sexual Disorders

Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS (clinicaltrials.gov) - P1 | N=144 | Recruiting | Sponsor: University of Virginia | Trial completion date: May 2024 ➔ May 2026 | Trial primary completion date: Apr 2024 ➔ Apr 2026

Trial completion date • Trial primary completion date • Polycystic Ovary Syndrome

Ovarian Contribution to Androgen Production in Adolescent Girls (clinicaltrials.gov) - P=N/A | N=80 | Active, not recruiting | Sponsor: University of Virginia | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2022 ➔ Dec 2025 | Trial primary completion date: Dec 2022 ➔ Dec 2025

Enrollment closed • Trial completion date • Trial primary completion date • Genetic Disorders • Obesity • Polycystic Ovary Syndrome

HCG Levels After Ovulation Triggering as Predictors of ICSI Outcome (clinicaltrials.gov) - P=N/A | N=100 | Completed | Sponsor: Mansoura University

New trial • Infertility • Sexual Disorders

A semi-automated hybrid HPLC-MS approach for in-depth characterization of intact non-covalent heterodimer glycoforms of gonadotropin biopharmaceuticals. (PubMed, Anal Chim Acta) - "Human chorionic gonadotropin (hCG) is sold as a biopharmaceutical under the name Pregnyl® (urinary hCG, u-hCG) and Ovitrelle® (recombinant hCG, r-hCG), and recombinant human follicle stimulating hormone (r-hFSH) is marketed as Gonal-f®...The results showed that these biopharmaceuticals differ considerably in their glycosylation patterns and highlight the importance of in-depth characterization of biopharmaceuticals for quality control."

Journal • Infertility • Sexual Disorders

CS-EOSP-ICSI: Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility (clinicaltrials.gov) - P1/2 | N=200 | Completed | Sponsor: Lebanese University | Active, not recruiting ➔ Completed | Phase classification: PN/A ➔ P1/2 | Trial completion date: Dec 2021 ➔ May 2023

Phase classification • Trial completion • Trial completion date • Endometriosis • Gynecology • Infectious Disease • Infertility • Polycystic Ovary Syndrome • Sexual Disorders • Uterine Leiomyoma • Women's Health

Progesterone Levels During Ovulation and Luteal Phase (clinicaltrials.gov) - P=N/A | N=6 | Completed | Sponsor: ART Fertility Clinics LLC | Recruiting ➔ Completed

Trial completion • Infertility • Sexual Disorders

Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS (clinicaltrials.gov) - P1 | N=144 | Recruiting | Sponsor: University of Virginia | Trial completion date: Dec 2023 ➔ May 2024 | Trial primary completion date: Dec 2023 ➔ Apr 2024

Trial completion date • Trial primary completion date • Polycystic Ovary Syndrome

Can Biotin Supplementation be Used to Mask hCG Abuse? (clinicaltrials.gov) - P1 | N=10 | Completed | Sponsor: Sports Medicine Research and Testing Laboratory | Recruiting ➔ Completed | Initiation date: Jul 2022 ➔ Oct 2022 | Trial primary completion date: Aug 2022 ➔ Feb 2023

Trial completion • Trial initiation date • Trial primary completion date

TIFFANY: Clinical Research Study to Learn About the Effect and Safety of Different Doses of FE 999302 When Given as a Single Dose for Final Development of the Eggs After Ovarian Stimulation (clinicaltrials.gov) - P2 | N=0 | Withdrawn | Sponsor: Ferring Pharmaceuticals | N=500 ➔ 0 | Suspended ➔ Withdrawn

Enrollment change • Trial withdrawal • Infertility • Sexual Disorders